Medicine

Johnson & Johnson Acquires Numab’s Investigational Antibody for the Treatment of Atopic Dermatitis

The acquisition of a novel therapy for atopic dermatitis includes an all-cash transaction totaling approximately $1.25 billion.

Leave a Reply

Your email address will not be published. Required fields are marked *